Registry update — unassessed
Metabolic Optimization and Training InterVentions for Aging and Type 2 Diabetes to Enhance Cognition: the MOTIVATE Study
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
RCTMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 20, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Research update
What it does not prove
- This is a study protocol describing planned research, not results—no efficacy of exercise or semaglutide on cognition has been demonstrated yet.
- The unequal intervention durations (32 weeks exercise vs. 16 weeks semaglutide) mean any cognitive benefits cannot be attributed to semaglutide alone without accounting for the differential treatment periods.
- The abstract does not report which cognitive outcomes are primary, how many participants are being enrolled, or what the statistical power is to detect meaningful effects.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 32 months
- Population
- Older adults with Type 2 diabetes
- Primary outcome
- Cognitive function
- Effect size
- —
- Significance
- Not reported
- Journal
- Western University, Canada
- Published
- Aug 20, 2026
Sources
Primary source
- Western University, Canada ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Type 2 diabetes and low levels of physical activity are associated with an increased risk of cognitive decline in older adults.
The MOTIVATE study is a randomized clinical trial designed to examine the effects of supervised exercise and diabetes treatment with semaglutide, alone or in combination, on cognitive function, physical health, and brain-related outcomes in older adults with Type 2 diabetes.
Participants will be assigned to one of four study groups involving exercise training, control exercise, semaglutide treatment, or standard diabetes care.
Participants will complete supervised exercise sessions three times per week for 32 weeks, with some participants also receiving weekly semaglutide injections for 16 weeks.
Assessments will include cognitive testing, physical and functional measures, blood-based metabolic markers, and brain imaging.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.